Atecegatran fexenetil

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAtecegatran fexenetil
Drug Alias NameAtecegatran metoxilAZD-0837AZD-7009AR-H065522
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel blockersSodium channel alpha subunit blockersVoltage-gated potassium channel subunit Kv1.5 blockers
TargetsPotassium channelSodium channel alpha subunitVoltage-gated potassium channel subunit Kv1.5
Therapy Area/IndicationsAtrial Fibrillation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenPolandNetherlands +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Uk LtdAstrazeneca PlcAstrazeneca Ab +[4] 
Active IndicationsN/A
Inactive IndicationsAtrial Fibrillation

Other Information

ATC CodeN/A
Related LinksN/A